You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Australia

Feb 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Sick Australia means a healthy industry

Between a severe hay fever season, an equally severe influenza season, and a boom in Australians holidaying overseas and contracting diarrhoea, Australians gave the consumer health market plentiful opportunities for growth at the end of the review period. Combining these factors with the increasing proportion of the population who are either old or obese and the associated health problems, and it is no surprise that consumer health in Australia experienced particularly strong growth in 2011, despite the economic turmoil.

Australia gets older and fatter

The ageing of Australia’s population, as Australia’s baby boomer generation approaches retirement, continues to be a major driver of growth in consumer health, as has Australia’s obesity epidemic, which shows no signs of abating. The combined impact of the two trends has been to drive growth across the board, including analgesics (particularly topical analgesics), digestive remedies, eye care products and vitamins and dietary supplements.

Sanofi-Aventis remains number one

With a portfolio of brands including many of the largest offerings in vitamins and dietary supplements (Nature’s Own, Cenovis) Sanofi-Aventis remained the leading player in consumer health in Australia in 2011, with Blackmores its closest competition.

Supermarkets expand their range

Although pharmacies remain by far the primary channel through which Australian consumers purchase consumer health products, and parapharmacies continue to build on their long-term gains, the importance of supermarkets expanded in 2011, as several popular brands were added. This was sometimes due to the removal of an active ingredient from the scheduling system, as in the case of Telfast in antihistamines/allergy remedies and Imodium in diarrhoeal remedies. On other occasions it was due to decisions by manufacturers to widen their distribution network, such as Nicorette in NRT smoking cessation aids being sold in Woolworths.

Consumer health rides demographic wave

Fuelled by underlying demographic trends, such as Australia’s ageing population and a rising numbers of births, as well as by lifestyle trends such as Australia’s growing obesity epidemic, and environmental factors such as a likely increase in the severity of hay fever and other allergies, consumer health in Australia is set to experience solid growth over the forecast period.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Australia with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Australia, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Australia for free:

The Consumer Health in Australia market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Australia?
  • What are the major brands in Australia?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in Australia - Industry Overview

EXECUTIVE SUMMARY

Sick Australia means a healthy industry

Australia gets older and fatter

Sanofi-Aventis remains number one

Supermarkets expand their range

Consumer health rides demographic wave

KEY TRENDS AND DEVELOPMENTS

Australian economy weakening

Ageing population

Birth Rate

The rise of the parapharmacy

Obesity

Australia sneezes

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Vitamins and dietary supplements’ registration and classification

Self-medication/self-care and preventive medicine

Switches

  • Summary 1 OTC – Switches 2009-2011

SOURCES

  • Summary 2 Research Sources

Consumer Health in Australia - Company Profiles

Blackmores Ltd in Consumer Health (Australia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 5 Blackmores Ltd: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 6 Blackmores Ltd: Competitive Position 2011

Ego Pharmaceuticals Pty Ltd in Consumer Health (Australia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 9 Ego Pharmaceuticals Pty Ltd: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 10 Ego Pharmaceuticals Pty Ltd: Competitive Position 2011

Herron Pharmaceuticals Pty Ltd in Consumer Health (Australia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 13 Herron Pharmaceuticals Pty Ltd: Competitive Position 2011

iNova Pharmaceuticals (Australia) Pty Ltd in Consumer Health (Australia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 15 iNova Pharmaceuticals (Australia) Pty Ltd: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 16 iNova Pharmaceuticals (Australia) Pty Ltd: Competitive Position 2011

Pharmacare Laboratories Pty Ltd in Consumer Health (Australia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 19 Pharmacare Laboratories Pty Ltd: Competitive Position 2011

Swisse Vitamins Pty Ltd in Consumer Health (Australia)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 21 Swisse Vitamins Pty Ltd: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 22 Swisse Vitamins Pty Ltd: Competitive Position 2011

Adult Mouth Care in Australia - Category Analysis

HEADLINES

TRENDS

  • The primary function of adult mouth care in Australia is the curing of mouth ulcers and canker sores, both of which represented increasing concerns in 2011. One impact of Australia’s ageing population has been the growing need for dentures, and therefore demand for adult mouth care products that assist with the related problem of denture rubbing. The mouth ulcers that often result from denture rubbing represent a major source of demand for adult mouth care products in Australia.

SWITCHES

COMPETITIVE LANDSCAPE

  • Bayer Australia Pty Ltd leads the category with two brands: Cepacaine and SM33, holding a combined value share of 37% in 2011.

PROSPECTS

  • As was the case in 2011, Australia’s ageing population and the growing dental problems that go along with this will be the primary driver of growth over the forecast period, driving a constant value CAGR of 4%. The high cost of dental care, and long waits for public dental services, means that many Australians only go to a dentist when absolutely necessary. The attitude that dental care is an expensive option has led to a worsening of Australia’s dental health, which is likely to continue over the forecast period. For most Australian consumers’ life dental care is considered to be not only expensive, but unnecessary. This changes as consumers reach old age, and it is this combination of an ageing population and lax attitudes in relation to dental health that will drive growth of adult mouth care over the forecast period.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in Australia - Category Analysis

HEADLINES

TRENDS

  • Driven largely by Australia’s ageing population and the growth in the number of Australians suffering from arthritis and other painful conditions associated with old age, analgesics grew by 5% in current value terms in 2011. Given then maturity of the category, one of the largest in consumer health, this rates as quite impressive growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • Nurofen from Reckitt Benckiser was the leading analgesic brand in Australia at the end of the review period, a leadership that expanded over 2011, rising to a value share of 23% from 22% in 2010. This is partially due to the growing popularity of ibuprofen as consumer concerns regarding the adverse effects of ibuprofen subside. As by far the dominant ibuprofen brand, Nurofen has been the prime beneficiary of this trend towards ibuprofen and away from acetaminophen, although the causality goes both ways, with ibuprofen’s popularity driven by Nurofen’s marketing.

PROSPECTS

  • As the number of elderly Australians continues to rise over the forecast period – with the number of over 65s tipped to increase from 2.8 million in 2011 to over three million in 2016, so the need to ease their arthritis- and rheumatism-related pain will increase. This will drive strong growth of analgesics, with a constant value CAGR of 3% over the forecast period. Topical analgesics will benefit most from this, due to the fact that they are specifically designed for arthritic relief, thus experiencing a constant value CAGR of 5% over the forecast period.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in Australia - Category Analysis

HEADLINES

TRENDS

  • Growing by 5% in 2011, down slightly compared with the performance of 2010, growth in calming and sleeping was at the end of the review period fuelled by growth in the incidence of insomnia in Australia. Although there are few precise figures on insomnia in Australia – those that do exist claim that 30% of Australians experience insomnia at any one time, with 50% experiencing insomnia at some stage in their life – underlying demographic and social factors suggest that the incidence is increasing, albeit slowly.

SWITCHES

COMPETITIVE LANDSCAPE

  • Dozile remained the leading brand in calming and sleeping in Australia at the end of the review period, a particularly impressive achievement given that much of its range is schedule three, and thus only available “behind-the-counter”.

PROSPECTS

  • As the number of Australians between the ages of 50 and 65 – the peak age segment for insomnia – increases from 4.1 million to 4.4 million over the forecast period, so will demand for calming and sleeping products. Much of this growth will come from herbal/traditional calming and sleeping products, as their widespread availability introduces the option to take a tablet for sleeping problems to a wider proportion of the market, including those with minor sleeping problems which are not severe enough to justify going to a doctor.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in Australia - Category Analysis

HEADLINES

TRENDS

  • The cough, cold and allergy (hay fever) remedies category in Australia is largely influenced by the Australian climate, which – although there are clear long-term trends – fluctuates from year to year. The end of the review period saw a particularly damp spring, for example, producing a particularly strong hay fever season, while cases of cold and flu also leapt considerably, particularly in Canberra and Cairns, as well as outside the traditional winter flu season. The latter was largely due to the impact of the Queensland floods over the summer of 2010/2011. This led to value growth of 5% in cough, cold and allergy (hay fever) remedies in 2011, up from the 3% increase seen in 2010, and the highest level of growth since 2002.

SWITCHES

COMPETITIVE LANDSCAPE

  • With brands including Zyrtec, Codral, Benadryl and Sudafed, Johnson & Johnson is the largest operator in cough, cold and allergy (hay fever) remedies in Australia, with a 19% value share in 2011 up from 18% in 2010. These advances were largely through heavy promotion of the Zyrtec brand in the fast-growing antihistamines/allergy remedies environment, giving Johnson & Johnson share gains in a growth category.

PROSPECTS

  • As the impact of climate change continues over the forecast period the length of the pollen season that effects Australian hay fever sufferers will increase as spring begins earlier. Thus, hay fever remedies are expected to see strong growth over the forecast period. With Telfast more easily available in Australian supermarkets, due to the switch of fexofenadine, this will further fuel growth. The impact of Telfast being available in supermarkets is expected to be considerable, largely due to the fact that hay fever is typically undertreated, with many sufferers putting up with their condition without treatment. With such treatment now significantly more easily accessible, and able to be picked up while shopping for other everyday products, hay fever remedies are likely to experience strong growth, with Telfast the main beneficiary.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in Australia - Category Analysis

HEADLINES

TRENDS

  • Digestive remedies experienced strong growth of 7% in 2011, with demand for laxatives, diarrhoeal remedies and indigestion and heartburn remedies all experiencing strong growth. There are several reasons for such strong growth, but Australia’s ageing population has the greatest influence. As consumers grow older they become more prone to such conditions as constipation as well as indigestion and heartburn, thereby generating 5% value growth in laxatives, as well as 9% growth in indigestion and heartburn remedies.

SWITCHES

COMPETITIVE LANDSCAPE

  • With brands including Imodium in diarrhoeal remedies, and Mylanta in antacids (both of which are rapidly growing categories), Johnson & Johnson extended its lead in digestive remedies, rising from an 18% value share in 2010 up to 20% in 2011. In the meantime, GlaxoSmithKline slipped from 16% in 2010 to 15%, its largest brand being Zantac in the slow-growing H2 blockers category. Whilst proton pump inhibitors, which were launched into the OTC environment in 2011, still have only a minor presence in Australia, it is Johnson & Johnson’s Pariet 10 brand that is dominant, thus providing further fuel to its growing leadership in digestive remedies.

PROSPECTS

  • As Australia’s baby boomer generation continues to age and becomes subject to the wide variety of digestive conditions, this will represent the prime driver of growth in digestive remedies over the forecast period, fuelling a constant value CAGR of 3%. Virtually all segments will benefit from this, including indigestion and heartburn remedies, which will experience a constant value CAGR of 4%, and laxatives, which are expected to see a constant value CAGR of 2%.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in Australia - Category Analysis

HEADLINES

TRENDS

  • The incidence of blocked ears, the primary reason for Australian consumers needing OTC ear care products, is on the increase in Australia. This was particularly the case in 2011 due to the severe hay fever season. Blocked ears are often a symptom of especially bad hay fever, and with the severity of the 2011 hay fever season ear care experienced 5% current value growth, up from the increases seen in 2009 and 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • Being such a small consumer health category there are few competitors in ear care, meaning that the combined share of the two largest brands represented more than half of total sales at the end of the review period. Norgine’s Waxsol brand led sales in 2011 with a value share of 28%, followed by Key Pharmaceuticals’ Ear Clear on 24%.

PROSPECTS

  • Having experienced two bad hay fever seasons in a row – 2010 and 2011 – it is increasingly apparent that due to climate change a high incidence of blocked ears is likely here to stay. This will drive solid growth in ear care, which is expected to see a constant value CAGR of 2% over the forecast period.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in Australia - Category Analysis

HEADLINES

TRENDS

  • Having been introduced into the Australian OTC market only in 2004, where it has remained in schedule three, meaning that it can only be sold “behind the counter” with the involvement of a pharmacist, emergency contraception is a category that is still forming, growing by 7% in current value terms in 2011. This performance was down from the 8% value growth of 2010, suggesting that having experienced strong growth in its early stages, demand for emergency contraception is beginning to plateau.

COMPETITIVE LANDSCAPE

  • Schering’s Postinor brand remained the only emergency contraception brand available in Australia at the end of the review period, and thus held a 100% share.

PROSPECTS

  • Although sexually transmitted infections (STIs) are largely increasing in Australia due in part to the increasingly lax attitude of Australian consumers in relation to safe sex, it is unlikely that such increased risk will change behaviour. STIs may be rising, but they are not rising to an adequate extent to create the level of paranoia and fear required to change sexual behaviour. As a result contraception will continue to centre on the contraceptive pill, even though this form of contraception can be unreliable. Many sexually active Australian women remain unaware that emergency contraception is available without a doctor’s prescription, and it is this that has held back the growth of emergency contraception. As awareness rises over the forecast period, so growth will continue, with a 3% constant value CAGR predicted.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2006-2011
  • Table 54 Sales of Emergency Contraception: % Value Growth 2006-2011
  • Table 55 Emergency Contraception Company Shares by Value 2007-2011
  • Table 56 Emergency Contraception Brand Shares by Value 2008-2011
  • Table 57 Forecast Sales of Emergency Contraception: Value 2011-2016
  • Table 58 Forecast Sales of Emergency Contraception: % Value Growth 2011-2016

Eye Care in Australia - Category Analysis

HEADLINES

TRENDS

  • The growth of eye care in 2011 was the result of a variety of causes, ranging from Australia’s ageing population to the growing amount of time Australians spend in front of computers. Women often experience “dry eyes” after menopause, often due to Sjogren’s Syndrome. Since 2011 a record number of Australian women have reached the age of menopause, driving significant growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • Allergan remained the largest player in eye care in Australia with a 33% value share in 2011. Much of this is due to the Refresh brand, which held a 14% value share at the end of the review period, while Cellufresh held 7%. Both of these brands compete in standard eye care, each with a similar position of targeting dry eye relief. Another Allergan brand, Albalon, with a 3% value share, is targeted at the treatment of red eyes. No brand dominates, however, demonstrating the fragmented nature of the eye care environment and the inability of any one brand to dominate any one selling proposition.

PROSPECTS

  • Eye care is expected to continue to experience the solid growth seen in 2010, with a constant value CAGR of 2% predicted for the forecast period. Each of the major factors driving growth in eye care – the growing incidence of dry eyes due to Australian women reaching menopause, and long hours spent at computers, as well as the likely repetition of the severe hay fever season of 2011 – are likely to continue over the forecast period.

CATEGORY DATA

  • Table 59 Sales of Eye Care by Category: Value 2006-2011
  • Table 60 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 61 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 62 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 63 Eye Care Company Shares by Value 2007-2011
  • Table 64 Eye Care Brand Shares by Value 2008-2011
  • Table 65 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 66 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in Australia - Category Analysis

HEADLINES

TRENDS

  • Due to concerns about taking artificial chemicals for insomnia, calming and sleeping is one of the key categories for herbal/traditional products in Australia. It is also the category to experience the strongest value growth, up 25% in 2011 – the fourth consecutive year that herbal/traditional sleeping and calming products experienced double-digit growth.

COMPETITIVE LANDSCAPE

  • With vitamins and dietary supplements making up the bulk of herbal/traditional products in Australia, this is reflected in the leading brands, with Blackmores and Nature’s Own leading. With virtually all medicated confectionery containing menthol, however, cough, cold and allergy remedy brands such as Allen’s and Vicks are also major players.

PROSPECTS

  • Herbal/traditional products only experienced a constant value CAGR of 2% over the review period, but this is expected to improve slightly to approaching 3% over the forecast period. Much of this will be driven by Australia’s ageing population, as consumers attempt to find convenient and affordable solutions to their deteriorating health, as well as issues such as brain function and memory. As long as Australian consumers feel they need extra nutrients, then they this trend will continue to drive demand for vitamins and dietary supplements. Furthermore, given that such a large proportion of that category is made up of herbal/traditional products, this will in turn drive growth.

CATEGORY DATA

  • Table 67 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 68 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 69 Herbal/Traditional Products Company Shares 2007-2011
  • Table 70 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 71 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 72 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in Australia - Category Analysis

HEADLINES

TRENDS

  • Value growth of 4% in medicated skin care in 2011 was largely generated by changes in Australia’s demographic mix, particularly in relation to age. Succinctly, growth was driven by the two fastest growing age groups: babies, the number of which peaked in 2010, and elderly Australians. The record number of babies in Australia in 2011 represented the major driver of the growth in nappy rash treatments, which grew by 8%, making nappy rash the fastest growing niche in medicated skin care.

SWITCHES

COMPETITIVE LANDSCAPE

  • With brands such as Regaine, Nizoral and Daktarin, Johnson & Johnson led sales at the end of the review period with a 20% value share. The company saw some weakening of its position in 2011, however, as each of these brands are either in segments in decline – such as hair loss treatments in the case of Regaine – or experiencing only weak growth, such as Nizoral in medicated shampoos or Daktarin in topical antifungals. The only major Johnson & Johnson brand to make any gains in 2011 was Anusol in haemorrhoid treatments, and this was only marginal.

PROSPECTS

  • Australia’s ageing population will continue to represent the main driver of growth in medicated skin care over the forecast period, fuelling a constant value CAGR of 2%. The need for topical germicidals/antiseptics in order to treat the injuries that result from increasingly common accidents such as falls will ensure strong growth, with a CAGR of 3% expected over the forecast period. Similarly haemorrhoid treatments is expected to see a strong constant value CAGR of 2%. This performance will be bolstered by the lack of fibre in the Australian diet. As it is unlikely that the threat of haemorrhoid trouble will convince Australians to improve their diet, continued strong growth is virtually assured.

CATEGORY DATA

  • Table 73 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 74 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 75 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 76 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 77 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 78 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 79 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in Australia - Category Analysis

HEADLINES

TRENDS

  • NRT smoking cessation aids experienced significant growth of 7% in current value terms in 2011, driven by a variety of factors, each one fuelling more growth. The first of these was the growing availability of these products through supermarkets. Until 2011 Nicabate was the only NRT smoking cessation aid product available in supermarkets, but 2011 saw Nicorette enter this channel, leading to greater awareness of the category. Within supermarkets, however, Nicorette was only available in Woolworths at the end of the review period, the largest of the two dominant supermarket chains in Australia, and was not available through Coles. This is likely to be temporary, however, with Coles expected to be added in 2012.

SWITCHES

COMPETITIVE LANDSCAPE

  • Nicabate by GlaxoSmithKline has long been the leading brand in NRT smoking cessation aids in Australia, assisted by being the only brand distributed through supermarkets. With the supermarket channel making up 24% of sales, up from 18% in 2010, this has given it an advantage over its closest competition, Nicorette, who continued to focus on pharmacies at the end of the review period.

PROSPECTS

  • Although the rate of smoking in Australia is among the lowest in the world, there is still a large proportion of the population who have not yet given up smoking. Many consumers who have given up smoking have found cessation aids to be one of the most successful and therefore most popular means of doing so. The continued success of these products is likely to result in NRT smoking cessation aids achieving a constant value CAGR of 5% over the forecast period, with the “plain packaging” legislation and 25% tax increase for cigarettes being important contributory factors.

CATEGORY INDICATORS

  • Table 80 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 81 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 82 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 83 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 84 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 85 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

Sports Nutrition in Australia - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition products saw greater mainstream use in Australia over the review period. This trend continued during 2011. The category used to be the domain of elite athletes and body builders, however industry players have expanded the category’s positioning to target recreational athletes, fitness enthusiasts and consumers with more general health and wellness goals. This repositioning significantly broadened the target demographic that this category reaches, which in turn led to significant value growth. The category has also benefited from growing health and wellness concerns and greater sports participation among consumers. For example, as health and wellness concerns grew in importance in Australia, consumers have started to use sports nutrition products to achieve personal fitness goals more quickly. The category grew by 10% in current value terms in 2011 to reach A$368 million.

COMPETITIVE LANDSCAPE

  • Nestlé Australia Pty Ltd is the leading domestic player in sports nutrition in Australia with a 10% value share in 2011. The company has a strong presence in supermarkets, chemists/pharmacies, online and in parapharmacies through its two sports nutrition brands Musashi and Powerbar. Nestlé Australia Pty Ltd has launched a ground-breaking water-based (as opposed to dairy-based) sports nutrition range called H2O, which includes both protein and non-protein offerings; UHT milk was previously the preferred vehicle for protein drinks. The H2O range was launched in 2011 under the Musashi umbrella name and contributed to Nestlé Australia Pty Ltd’s strong sales growth that year. The Musashi brand faces tough competition from Vitaco Health Australia Pty Ltd’s Aussie Bodies brand within the grocery channel. The Musashi brand has also enjoyed success with its convenience-oriented products. The Musashi brand is leader in sales value terms for both protein bars and RTD protein products. Nestlé Australia Pty Ltd has seen success by promoting a mainstream image and distributing products through supermarkets and chemists/pharmacies, however, within healthcare specialists, healthfood stores and other non-grocery retail channels such as gyms, the Musashi brand faces tough competition from brands such as Horleys and BSN, which have a more out-and-out, uncompromising, gym-goer focus.

PROSPECTS

  • Use of sports nutrition products will become increasingly mainstream over the forecast period. Increased availability of sports nutrition products, particularly with the aid of greater supermarket distribution, will help drive growth. Greater availability of information regarding sports nutrition products and more frequent use by other athletes will help break down the barriers consumers have towards the category and encourage more mainstream use. Sports nutrition is expected to see a 6% constant value CAGR over the forecast period.

CATEGORY DATA

  • Table 88 Sales of Sports Nutrition: Value 2006-2011
  • Table 89 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 90 Sports Nutrition Company Shares 2007-2011
  • Table 91 Sports Nutrition Brand Shares 2008-2011
  • Table 92 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 93 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in Australia - Category Analysis

HEADLINES

TRENDS

  • Vitamins and dietary supplements grew by 7% in 2011 to be valued at A$1.4 billion. Health and wellness trends in Australian society have encouraged consumers to take greater care of their health, and maintain optimal nutritional condition. Vitamins and dietary supplements also benefited from consumers who were keen to act pre-emptively to avoid suffering illness in the midst of busy urban lifestyles. This was coupled with increased awareness that some grocery food products consumed in Australia do not provide all the necessary vitamins and minerals.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Sanofi-Aventis Healthcare Pty Ltd was the leading brand in vitamins and dietary supplements in Australia in 2011 with a 27% value share. The company has five brands in the category: Nature’s Own, Cenovis, Bio-Organics, Golden Glow and Ostelin. With these four brands the company is represented in each niche within dietary supplements. The company also benefits from broad retail distribution as its offerings are available online, in supermarkets, chemist/pharmacies and through healthfood stores.

PROSPECTS

  • The vitamins and dietary supplements category is expected to become increasingly segmented in terms of product offerings over the forecast period. This will be driven by players looking to offer increasingly customised solutions to consumers’ health and wellness concerns. Frequent new product launches will help industry players differentiate their offerings from those of their competitors.

CATEGORY DATA

  • Summary 23 Dietary Supplements: Brand Ranking by Positioning 2011
  • Table 94 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 95 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 96 Dietary Supplements by Positioning 2006-2011
  • Table 97 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 98 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 99 Vitamins Brand Shares by Value 2008-2011
  • Table 100 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 101 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 102 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in Australia - Category Analysis

HEADLINES

TRENDS

  • Weight management saw declining sales in 2011, due primarily to weakening demand for meal replacement slimming products. The category declined to A$334 million in 2011. The category saw growth in weight loss supplements and over-the-counter (OTC) weight loss categories, but value decline in meal replacement slimming and in other slimming products. Consumers appreciate the convenience and efficacy of weight loss supplements and OTC weight loss offerings, while also placing less efficacy on other slimming products.

COMPETITIVE LANDSCAPE

  • Tony Ferguson is the leading player in Australian weight management, accounting for 11% of sales in 2011. The Tony Ferguson brand has good retail distribution as it is sold through Terry White Chemists, Tony Ferguson Weightloss & Wellness centres, as well as via the Internet. The company had significant marketing activity over the review period, opening a number of stores and seeing significant sales growth. The high public profile of these stores helped encourage the use of Tony Ferguson products and also promote the weight management category in general. The excellent sales growth seen following the launch of the Tony Ferguson clinics proved unsustainable. The Tony Ferguson brands conformed to the prevailing trend over much of the later stages of the review period, which was to experience a decline in sales value.

PROSPECTS

  • The weight management category is expected to see constant value CAGR of 1% over the forecast period. Growth in weight loss supplements and meal replacement slimming will drive this growth as consumers appreciate the efficacy and ease of use of these respective products.

CATEGORY DATA

  • Table 103 Sales of Weight Management: Value 2006-2011
  • Table 104 Sales of Weight Management: % Value Growth 2006-2011
  • Table 105 Weight Management Company Shares 2007-2011
  • Table 106 Weight Management Brand Shares 2008-2011
  • Table 107 Forecast Sales of Weight Management: Value 2011-2016
  • Table 108 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in Australia - Category Analysis

HEADLINES

TRENDS

  • Wound care grew by 5% in current value terms in 2011, up from the 4% increase seen in 2010. This was fuelled largely by Australia’s ageing population and the injuries that often occur as a result of ageing. As consumers get older a number of factors combine to increase demand for wound care: not only are they increasingly prone to falls, but it also takes longer for wounds to heal. Particularly boosted by the ageing population is gauze, tape and other wound care, which are typically used for such injuries. This category grew 8% in current value terms in 2011, following similarly high 6% growth in 2010.

COMPETITIVE LANDSCAPE

  • While Johnson & Johnson’s Band-Aid brand has long been the leader in wound care, remaining so with a 27% value share in 2011 despite falling from 28% in 2010, this lead has slowly been eroded by the Beiersdorf brand Elastoplast, which has its strength in both gauze, tape and other wound care and sticking plasters and adhesive bandages. Elastoplast, which specialises in fabric rather than plastic bandages, is more hardy and robust than Band-Aid, and it is this durability that it has pushed in branding. It encourages consumers to be active and make the most of their lives with taglines such as “defy your limits”, and a range branded Extreme. The aim is to reassure consumers that Elastoplast can help with any consequent injuries. It is this strategy that led to Elastoplast making gains from 25% in 2010 to practically be neck-and-neck with Band-Aid on 26% in 2011. Whilst Elastoplast builds on its association with supporting activities, under the tagline “supporting your passion”, Band-Aid is largely relying on its heritage as a family brand that Australians feel comfortable with.

PROSPECTS

  • As Australian’s population becomes older they will gradually require wound care more frequently. This goes both for elderly Australians experiencing a greater propensity for falls as well as middle-aged Australians attempting to retain their youth by engaging in physical exercise their bodies struggle with. This is expected to be the primary driver of growth over the forecast period, and the reason for constant value CAGR of 2%.

CATEGORY DATA

  • Table 109 Sales of Wound Care by Category: Value 2006-2011
  • Table 110 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 111 Wound Care Company Shares by Value 2007-2011
  • Table 112 Wound Care Brand Shares by Value 2008-2011
  • Table 113 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 114 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Milk Thistle
            • Saw Palmetto
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Paediatric Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Paediatric Consumer Health
        • Paediatric Analgesics
          • Paediatric Acetaminophen
          • Paediatric Aspirin
          • Paediatric Combination Products - Analgesics
          • Paediatric Diclofenac
          • Paediatric Dipyrone
          • Paediatric Ibuprofen
          • Paediatric Ketoprofen
          • Paediatric Naproxen
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Paediatric Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Paediatric Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market sizes
    • Company shares
    • Brand shares
    • Distribution
    • Analysis by format
    • Analysis by positioning
    • Analysis by type
    • Herbal/traditional vs standard
    • Pricing
    • Smoking population - number of adult smokers
    • Smoking prevalence - % of adult population

    Market size details:

    • Retail volume
    • Retail volume % growth
    • Retail volume per capita
    • Retail value retail selling price % growth
    • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price % growth
    • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?

    If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!